Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008;13(6):799-807.

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial

Michael H Chung  1 , James N Kiarie, Barbra A Richardson, Dara A Lehman, Julie Overbaugh, John Kinuthia, Francis Njiri, Grace C John-Stewart
Affiliations
Clinical Trial

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial

Michael H Chung et al. Antivir Ther. 2008.

Abstract

Background: Defining the effect of antiretroviral regimens on breast milk HIV type-1 (HIV-1) levels is useful to inform the rational design of strategies to decrease perinatal HIV-1 transmission.

Methods: Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to breastfeed in Nairobi, Kenya were randomized to highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine and nevirapine [NVP]) during pregnancy and 6 months post-partum or to short-course ZDV plus single-dose NVP (ZDV/NVP). Breast milk samples were collected two to three times per week in the first month post-partum.

Results: Between November 2003 and April 2006, 444 breast milk samples were collected from 58 randomized women during the first month after delivery. Between 3 and 14 days post-partum, women in the HAART and ZDV/NVP arms had a similar prevalence of undetectable breast milk HIV-1 RNA. From 15 to 28 days post-partum, women in the HAART arm had significantly lower levels of breast milk HIV-1 RNA than women randomized to ZDV/NVP (1.7 log10 copies/ml [limit of detection] versus >2.10 log10 copies/ml, P<0.001). In contrast to breast milk HIV-1 RNA, suppression of plasma HIV-1 RNA during the neonatal period was consistently several log10 greater in the HAART arm compared with the ZDV/NVP arm.

Conclusions: HAART resulted in lower breast milk HIV-1 RNA than ZDV/NVP; however, ZDV/NVP yielded comparable breast milk HIV-1 RNA levels in the first 2 weeks post-partum. Breast milk HIV-1 RNA remained suppressed in the ZDV/NVP arm despite increased plasma HIV-1 levels, which might reflect local drug effects or compartmentalization.

Trial registration: ClinicalTrials.gov NCT00167674.

PubMed Disclaimer

Conflict of interest statement

None of the authors has a major conflict of interest in this study.

Figures

Figure 1
Figure 1. Trial Profile
Figure 2
Figure 2. Proportion of women with undetectable HIV-1 RNA in breast milk
Figure 3
Figure 3. Mean log10 HIV-1 RNA copies in breast milk and plasma over days postpartum
Solid lines and crosses = AZT/NVP arm. Dashed lines and circles = HAART arm.
See this image and copyright information in PMC

References

    1. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283:1167–1174. - PubMed
    1. WHO. HIV and infant feeding technical consultation, October 25-27, 2006. Geneva: World Health Organization; 2006.
    1. Sinkala M, Kuhn L, Kankasa C, Kasonde P, Vwalika C, Mwiya M, et al. No Benefit of Early Cessation of Breastfeeding at 4 Months on HIV-free Survival of Infants Born to HIV-infected Mothers in Zambia: The Zambia Exclusive Breastfeeding Study. Fourteenth Conference on Retroviruses and Opportunistic Infections; Los Angeles. 2007.
    1. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006;296:794–805. - PubMed
    1. John-Stewart G, Mbori-Ngacha D, Ekpini R, Janoff EN, Nkengasong J, Read JS, et al. Breast-feeding and Transmission of HIV-1. J Acquir Immune Defic Syndr. 2004;35:196–202. - PMC - PubMed

Publication types

MeSH terms

Associated data